StudyFinder

Standardizing Treatments for Pulmonary Exacerbations - Aminoglycoside Study

RECRUITING
I'm interested

6 years and over
This study is NOT accepting healthy volunteers
Inclusion Criteria:
* All genders ≥ 6 years of age at Visit 1 * Documentation of a CF diagnosis * Clinician intent to treat index CF PEx with a planned 14-day course of IV antimicrobials * At least one documented Pa positive culture within two years prior to Visit 1
Exclusion Criteria:
* Participant is not pregnant * No known renal impairment or history of solid organ transplantation * No IV antimicrobial treatment, ICU admission, pneumothorax, or hemoptysis within 6 weeks prior to Visit 1 * No use of investigational therapies, new CF transmembrane conductance regulator (CFTR) modulators, or treatment for Nontuberculous mycobacteria (NTM) within 4 weeks prior to Visit 1 * No history of hypersensitivity, vestibular, or auditory toxicity with aminoglycosides * No more than one day of IV aminoglycosides administered for the current PEx treatment prior to Visit 1

DRUG: Beta-lactam antibiotic, DRUG: Aminoglycoside

Cystic Fibrosis, Cystic Fibrosis Pulmonary Exacerbation

Cystic Fibrosis, CF, Cystic Fibrosis Pulmonary Exacerbation, aminoglycoside, beta-lactam, β-lactam, STOP, STOP360

Rachael Buckingham, BS - Rachael.buckingham@seattlechildrens.org
PHASE4
NCT05548283

Back